Several in vivo and in vitro studies highlighted the central role of α-SMA+ CAFs in CCA promotion and drug resistance [54], and clinical studies indicated a correlation between high CCA CAF numbers with poor patient survival [55]. Here, ACTA1 is linked to cholangiocarcinoma.